A-Phenicol0.5%

Ophthalmic (Eye Drops / Eye Ointment) — Established Use

A-Phenicol 0.5% eye drops (0.5%) and eye ointment (1%) are indicated for the treatment of superficial bacterial infections of the eye, including bacterial conjunctivitis and other infections of the conjunctiva and/or cornea caused by susceptible organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Moraxella lacunata, and Neisseria species. This is an established, guideline-supported first-line topical use. A-Phenicol 0.5% eye preparations should not be used for minor infections that would resolve on their own or purely for prophylaxis.

Oral (Capsule / Suspension) — Reserved for Serious Infections

Oral A-Phenicol 0.5% is reserved for serious, potentially life-threatening infections caused by organisms susceptible to A-Phenicol 0.5%, specifically when safer or less hazardous antimicrobial agents are ineffective, contraindicated, or unavailable. Established/guideline-referenced serious indications include typhoid fever (Salmonella typhi and other Salmonella species), bacterial meningitis due to Haemophilus influenzae, and severe rickettsial infections. Oral A-Phenicol 0.5% should never be used for trivial infections such as the common cold, viral influenza, or uncomplicated sore throat, and not used prophylactically. Because of the risk of fatal bone marrow toxicity (see Precautions and Warnings), oral A-Phenicol 0.5% is used only under close medical and haematological supervision.

Each formulation contains A-Phenicol 0.5% as the sole active ingredient. In Bangladesh, A-Phenicol 0.5% is marketed as: Ophthalmic solution (eye drops) containing A-Phenicol 0.5% 0.5% w/v; Ophthalmic ointment containing A-Phenicol 0.5% 1% w/w; Oral capsule containing A-Phenicol 0.5% 250 mg; and Oral suspension containing A-Phenicol 0.5% 125 mg/5 mL.

A-Phenicol 0.5% is a broad-spectrum antibiotic used in two very different ways depending on the formulation. As an eye drop or eye ointment, A-Phenicol 0.5% is a common, generally well-tolerated treatment for bacterial conjunctivitis and other superficial eye infections. As an oral capsule or suspension, A-Phenicol 0.5% is a powerful antibiotic reserved for serious infections, such as typhoid fever, when safer antibiotics cannot be used, because systemic A-Phenicol 0.5% carries a rare but serious risk of fatal bone marrow toxicity (aplastic anemia) and, in newborns, a life-threatening reaction called Gray baby syndrome. For these reasons, oral A-Phenicol 0.5% should only be used under close medical supervision, while topical/ophthalmic A-Phenicol 0.5% continues to be widely used for eye infections.

Antibiotic (Amphenicol) — topical/ophthalmic and systemic antibacterial

A-Phenicol 0.5% is a broad-spectrum, predominantly bacteriostatic antibiotic. A-Phenicol 0.5% diffuses into bacterial cells and reversibly binds the 50S ribosomal subunit, blocking the peptidyl transferase reaction and preventing transfer of amino acids to growing peptide chains, thereby inhibiting bacterial protein synthesis. This action covers a broad range of gram-positive and gram-negative organisms, as well as rickettsiae and some anaerobes. After an oral dose, A-Phenicol 0.5% is well absorbed, achieving peak plasma concentrations of roughly 11 mcg/mL within 1–3 hours of a 1 g dose. A-Phenicol 0.5% distributes widely, including into the liver, kidney, and cerebrospinal fluid (crossing the blood–brain barrier even without meningeal inflammation), and is metabolised mainly in the liver by glucuronidation. Because hepatic glucuronidation capacity is immature in neonates and young infants, A-Phenicol 0.5% can accumulate to toxic levels in this age group (see Gray baby syndrome under Pediatric Uses). After ophthalmic application, systemic absorption is minimal, so systemic pharmacokinetic effects are not usually relevant to the topical/ophthalmic formulations.

Using A-Phenicol 0.5% Eye Drops

• Wash your hands before and after use.
• Tilt your head back and gently pull the lower eyelid down with a clean finger to form a small pocket.
• Hold the bottle close to the eye without touching it, and let one drop fall into the pocket.
• Close the eye and press a finger gently on the inner corner of the eye for about a minute to reduce drainage.
• Wipe away any excess with a clean tissue; do not touch the dropper tip to the eye or any surface.
• If using more than one type of eye drop, space them at least 5 minutes apart.
• Store the bottle as directed on the label; some A-Phenicol 0.5% eye drop products require refrigeration once opened.

Using A-Phenicol 0.5% Eye Ointment

• Wash your hands before and after use.
• Tilt your head back and gently pull down the lower eyelid.
• Hold the tube close to (without touching) the eye and squeeze a small (~1 cm) ribbon of ointment into the space between the lower lid and the eye.
• Close the eye and blink gently to help spread the ointment; vision may blur briefly after application.
• Applying at bedtime is often preferred, since the ointment stays in contact with the eye surface longer during sleep.

Using Oral A-Phenicol 0.5% (Capsule / Suspension)

• Take capsules with a full glass of water.
• Shake the oral suspension well before every dose and measure the dose with an accurate oral measuring device, not a household spoon.
• Try to take doses at evenly spaced intervals (commonly every 6 hours) to maintain steady blood levels.
• Complete the full course exactly as prescribed, and do not stop early or extend the course, unless directed by the prescriber.
• Do not share A-Phenicol 0.5% with others or use leftover doses for a different illness.

Contact Lens Advice (Ophthalmic Use)

• Remove contact lenses before applying A-Phenicol 0.5% eye drops or ointment.
• Wait at least 24 hours after the last dose before reinserting soft contact lenses, unless your prescriber advises otherwise.

• Phenytoin: A-Phenicol 0.5% inhibits hepatic metabolism of phenytoin, which can raise phenytoin blood levels and increase the risk of phenytoin toxicity; dose adjustment and monitoring may be needed.
• Warfarin / dicoumarol-type anticoagulants: A-Phenicol 0.5% inhibits hepatic metabolism of these anticoagulants, potentiating their effect and increasing bleeding risk; closer INR monitoring is advised during concurrent use.
• Tolbutamide and related sulfonylureas: A-Phenicol 0.5% slows the metabolism of these oral hypoglycemic agents, which can enhance their blood-glucose-lowering effect and increase hypoglycemia risk.
• Cyclophosphamide: A-Phenicol 0.5% may inhibit the hepatic metabolism required to activate cyclophosphamide, potentially altering its effect; use together only with medical guidance.
• Rifampin: Rifampin induces hepatic enzymes that metabolise A-Phenicol 0.5%, which can lower A-Phenicol 0.5% blood concentrations and reduce A-Phenicol 0.5%'s antibacterial effect.
• Other bone-marrow-suppressing drugs (e.g., certain antineoplastic agents): Concurrent use with A-Phenicol 0.5% increases the risk of additive bone marrow suppression and should generally be avoided (see Precautions and Warnings — bone marrow toxicity).
• Erythromycin, clindamycin, or lincomycin: Because these antibiotics act on an overlapping ribosomal binding site, concurrent use with A-Phenicol 0.5% may antagonise each drug's antibacterial activity; concurrent use is generally avoided.
• Vitamin B12, iron, or folic acid used for anemia: A-Phenicol 0.5% may blunt the hematologic response to these agents when they are used to treat anemia during A-Phenicol 0.5% therapy.
• Chymotrypsin (ophthalmic use): When A-Phenicol 0.5% eye preparations are used together with ophthalmic chymotrypsin, chymotrypsin's activity may be inhibited.

Ophthalmic (Eye Drops / Eye Ointment)

Common: Transient burning or stinging on application, eye redness (conjunctival hyperemia), itching, and mild irritation.

Serious — seek medical attention: Signs of allergic or hypersensitivity reaction (rash, swelling, vesicular or maculopapular dermatitis around the eye); with prolonged or repeated ophthalmic courses, rare blood dyscrasias have been reported (see Precautions and Warnings — bone marrow toxicity) — stop A-Phenicol 0.5% and seek medical advice if unusual bruising, bleeding, or infection symptoms occur.

Oral (Capsule / Suspension)

Common: Nausea, vomiting, diarrhea, and headache; mild skin rash.

Serious — seek medical attention immediately: Signs of bone marrow suppression or aplastic anemia such as unusual bruising or bleeding, sore throat, fever, or unusual tiredness (see Precautions and Warnings for the full explanation); optic neuritis (blurred or reduced vision) and peripheral neuropathy with prolonged therapy; signs of Gray baby syndrome in neonates and young infants — abdominal distension, vomiting, progressive grey-blue skin colour, low body temperature, and cardiovascular collapse (see Pediatric Uses); and signs of severe hypersensitivity/anaphylaxis (difficulty breathing, facial swelling, severe rash).

Pregnancy

Data on A-Phenicol 0.5% use in human pregnancy are limited; controlled studies have not established the safety of A-Phenicol 0.5%, and animal reproduction data are not well characterised. A-Phenicol 0.5% crosses the placenta. The most important documented concern is use late in pregnancy, close to delivery, which has been associated with adverse effects in the neonate resembling Gray baby syndrome due to the newborn's immature ability to metabolise A-Phenicol 0.5% (see Pediatric Uses). Because of this, A-Phenicol 0.5%, particularly the oral/systemic form, should be used in pregnancy only if the potential benefit is judged by a physician to justify the potential risk to the fetus/neonate, and avoided close to term whenever an alternative exists. Topical/ophthalmic use has much lower systemic absorption, but should still only be used in pregnancy on a physician's advice.

Breastfeeding

Oral/systemic A-Phenicol 0.5% passes into breast milk in amounts that have caused adverse effects in nursing infants, including vomiting, excessive gas, and drowsiness at the breast; true Gray baby syndrome from breastfeeding alone is considered unlikely because milk concentrations are relatively low, but the idiosyncratic, non-dose-related risk of aplastic anemia cannot be excluded. Because of this, an alternative antibiotic is generally preferred during breastfeeding, especially for mothers of newborn or preterm infants; if oral A-Phenicol 0.5% is unavoidable, the infant should be monitored closely and a physician consulted. Topical/ophthalmic A-Phenicol 0.5% is not expected to reach the infant in clinically significant amounts, but should still be used only as advised by a physician.

• Bone marrow toxicity / aplastic anemia (canonical warning): Systemic A-Phenicol 0.5% can cause serious and sometimes fatal blood disorders. Two distinct patterns are recognised: a predictable, dose-related, reversible form causing mild anemia, low platelets, or low white cells that typically resolves after stopping A-Phenicol 0.5%; and a rare, unpredictable, dose-independent, and often irreversible form that can progress to fatal aplastic anemia, with a risk estimated at roughly 1 in 24,000 to 1 in 40,000 treated patients, sometimes appearing weeks to months after treatment has ended. Because of this risk, oral A-Phenicol 0.5% should be reserved for serious infections where safer alternatives are unsuitable, baseline and periodic blood counts (roughly every two days during therapy, per prescribing guidance) should be performed, and A-Phenicol 0.5% should be stopped promptly if reticulocytopenia, leukopenia, thrombocytopenia, or anemia appears. Prolonged or repeated ophthalmic use has also been rarely associated with blood dyscrasias, so repeated courses of A-Phenicol 0.5% eye drops/ointment should be avoided.
• Gray baby syndrome (neonates/infants): A potentially fatal toxicity in newborns and young infants who cannot adequately metabolise A-Phenicol 0.5%; see Pediatric Uses for the full explanation and warning signs.
• Reserve for serious infections: Oral A-Phenicol 0.5% should not be used for trivial infections, colds, viral influenza, or uncomplicated throat infections, and should not be used prophylactically, because A-Phenicol 0.5%'s serious toxicity is not justified when safer antibiotics are effective.
• Avoid repeated or prolonged courses: Whether topical or oral, repeated courses of A-Phenicol 0.5% increase the cumulative risk of blood dyscrasias and should be avoided; ophthalmic courses generally should not exceed about 3 weeks without medical re-evaluation.
• Hepatic and renal function: Because A-Phenicol 0.5% is metabolised in the liver and A-Phenicol 0.5% blood levels can rise with impaired clearance, dose adjustment and closer monitoring are recommended in patients with hepatic or renal impairment on the oral/systemic form.
• Avoid concurrent bone-marrow-suppressing drugs: Using A-Phenicol 0.5% together with other drugs that suppress bone marrow function increases the risk of additive blood toxicity (see Interactions).
• Neurotoxicity with prolonged therapy: Optic neuritis and peripheral neuropathy have been reported with prolonged systemic A-Phenicol 0.5% use; report any change in vision or unusual numbness/tingling to a doctor promptly.

No specific toxic-dose threshold for A-Phenicol 0.5% has been firmly established, and overdose effects vary with the formulation, dose, and patient age. Reported effects of significant oral/systemic overdose include gastrointestinal upset (nausea, vomiting), and — particularly in neonates, infants, or with very high systemic exposure — features resembling Gray baby syndrome, such as abdominal distension, poor feeding, low body temperature, progressive grey-blue skin colour, metabolic acidosis, and cardiovascular collapse, which is a medical emergency. There is no specific antidote; management is supportive and is provided in a hospital setting. If an overdose of A-Phenicol 0.5% (oral or, less likely, ophthalmic) is suspected, do not induce vomiting unless specifically directed to do so by a doctor or poison control service, and seek emergency medical attention or contact the national poison information/emergency service immediately, taking the A-Phenicol 0.5% packaging with you.

Store A-Phenicol 0.5% according to the instructions on the product label. As a general guide, keep oral capsules and suspension in a cool, dry place away from direct light and heat, and keep the suspension tightly closed; some A-Phenicol 0.5% eye drop products should be refrigerated once opened and discarded after the period stated on the label (commonly within about 4 weeks of opening) — check the specific product's label, as storage requirements can differ between brands. Keep all A-Phenicol 0.5% products out of the sight and reach of children, and do not use after the expiry date.

Children

For ophthalmic A-Phenicol 0.5%, dosing is generally the same in children as in adults, following the same drop/ointment instructions under a doctor's guidance. For oral/systemic A-Phenicol 0.5%, dosing beyond the neonatal period is weight-based (see Dosage table), but this age group is at particular risk of Gray baby syndrome if metabolism is immature or dosing is excessive — see Pediatric Uses for the full explanation.

Elderly

Specific dosing studies in the elderly are limited. Because bone marrow toxicity risk from systemic A-Phenicol 0.5% is not clearly age-related but overall physiological reserve and organ function often decline with age, oral A-Phenicol 0.5% should be used cautiously in elderly patients, with attention to hepatic and renal function and closer haematological monitoring.

Renal Impairment

Dose adjustment and more frequent monitoring are recommended for oral/systemic A-Phenicol 0.5% in patients with renal impairment, individualised by the treating physician. Ophthalmic A-Phenicol 0.5% is not expected to require adjustment given minimal systemic absorption.

Hepatic Impairment

Because A-Phenicol 0.5% is cleared mainly by the liver, hepatic impairment can lead to drug accumulation and increased toxicity risk with the oral/systemic form; dose reduction and closer monitoring are recommended. Ophthalmic A-Phenicol 0.5% is not expected to require adjustment given minimal systemic absorption.

Duration of A-Phenicol 0.5% therapy is determined by the treating healthcare professional based on the specific infection and the patient's response, and is not the same for every use. For ophthalmic A-Phenicol 0.5%, a typical course is about 7 days, and courses should not exceed roughly 3 weeks without medical re-evaluation. For oral/systemic A-Phenicol 0.5%, treatment is generally kept as short as clinically effective given the serious risks of prolonged therapy, and repeated or extended courses should be avoided unless specifically directed by a physician monitoring blood counts.

Amphenicol antibiotics; broad-spectrum antibacterial agents.

A-Phenicol 0.5% diffuses into bacterial cells and binds reversibly to the 50S subunit of the bacterial ribosome, at a site close to the peptidyl transferase centre. This blocks the peptidyl transferase reaction, preventing the transfer of amino acids to the growing peptide chain and thereby inhibiting bacterial protein synthesis. This action is predominantly bacteriostatic across most susceptible organisms.

Gray baby syndrome (canonical explanation): Newborns, especially premature infants, and young infants have immature liver glucuronidation and kidney function, meaning they cannot clear A-Phenicol 0.5% as efficiently as older children or adults. When systemic (oral or injectable) A-Phenicol 0.5% accumulates in this age group — from high doses, prolonged therapy, or use in the neonatal period without appropriate dose reduction and monitoring — this accumulation of A-Phenicol 0.5% can cause a toxic reaction known as Gray baby syndrome. This typically appears after about 3–4 days of high-dose therapy and is characterised by poor feeding, abdominal distension with or without vomiting, irritability, progressive pallid or grey-blue skin discolouration, low body temperature, and vasomotor/cardiovascular collapse, which can be fatal if not recognised and treated promptly; stopping A-Phenicol 0.5% immediately may allow reversal if caught early. Because of this risk, systemic A-Phenicol 0.5% in neonates and young infants must only be given under specialist (paediatric/neonatal) supervision, with dosing individualised to the infant's age and, where available, serum drug-level monitoring, and systemic A-Phenicol 0.5% should be avoided altogether when a safer alternative antibiotic can be used.

Older infants and children: Beyond the neonatal period, oral A-Phenicol 0.5% is dosed by body weight (see Dosage table) but remains reserved for serious infections where safer antibiotics are unsuitable, because of the same bone-marrow-toxicity risk that applies to adults (see Precautions and Warnings). Ophthalmic A-Phenicol 0.5% eye drops/ointment are commonly used in children of all ages for bacterial conjunctivitis, following the same instructions as for adults, under a doctor's or pharmacist's guidance.